Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026)
Nuvectis Pharma (NVCT) posted Income from Continuing Operations of 7144000.0 for Q1 2026, up 14.39% sequentially from 8345000.0 in Q4 2025, and little changed YoY from 7152017.96 in Q1 2025.
Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Income from Continuing Operations for 6 years, with the latest figure at 7144000.0 in Q1 2026.
- Quarterly Income from Continuing Operations changed 0.11% year-over-year to 7144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30786000.0 (up 27.89% YoY) and the FY2025 annual result came in at 27473000.0, up 28.69% from the prior year.
- Income from Continuing Operations climbed to 7144000.0 in Q1 2026 per NVCT's latest filing, from 8345000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3930000.0 in Q1 2022 and troughed at 25776000.0 in Q4 2024.
- A 5-year average of 11012941.18 and a median of 8345000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 303.28% in 2023, then jumped 73.86% in 2024.
- Over 5 years, Income from Continuing Operations stood at 15269000.0 in 2022, then tumbled by 38.27% to 21113000.0 in 2023, then dropped by 22.09% to 25776000.0 in 2024, then jumped by 67.62% to 8345000.0 in 2025, then rose by 14.39% to 7144000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7144000.0, 8345000.0, and 7960000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.02 Mn |
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | -7.96 Mn |
| Jun 30, 2025 | -7.34 Mn |
| Mar 31, 2025 | -7.14 Mn |
| Dec 31, 2024 | -25.78 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -5.03 Mn |
| Mar 31, 2024 | -13.81 Mn |
| Dec 31, 2023 | -21.11 Mn |
| Sep 30, 2023 | -18.15 Mn |
| Jun 30, 2023 | -9.70 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.27 Mn |
| Sep 30, 2022 | -8.64 Mn |
| Jun 30, 2022 | -7.28 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Sep 30, 2021 | -4.67 Mn |